Adimmune Corporation reported its consolidated financial results for the first quarter of 2026 to the Board of Directors on May 13. For the period from January 1 to March 31, the company posted a cumulative operating revenue of NT$82.31 million. It recorded an operating gross loss of NT$74.55 million and an operating loss of NT$199.21 million. The net loss attributable to owners of the parent was NT$185.54 million, resulting in a basic loss per share of NT$0.44. Total assets stood at NT$7.82 billion.